These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 8636752)

  • 21. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
    Gradishar WJ
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
    Fumoleau P; Chevallier B; Kerbrat P; Krakowski Y; Misset JL; Maugard-Louboutin C; Dieras V; Azli N; Bougon N; Riva A; Roche H
    Ann Oncol; 1996 Feb; 7(2):165-71. PubMed ID: 8777173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
    Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
    J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of docetaxel/doxorubicin combination in metastatic breast cancer.
    Diéras V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):31-3. PubMed ID: 9364539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of taxanes in the treatment of breast cancer.
    Capri G; Tarenzi E; Fulfaro F; Gianni L
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
    Alexopoulos A; Kouroussis C; Malamos N; Kakolyris S; Kalbakis K; Kosmas C; Mavroudis D; Agelaki S; Vlachonicolis J; Sarra E; Rigatos G; Georgoulias V
    Ann Oncol; 2001 Jun; 12(6):793-8. PubMed ID: 11484954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
    Pagani O; Sessa C; Nolè F; Crivellari D; Lombardi D; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Zucchetti M; D'Incalci M; Goldhirsch A
    Ann Oncol; 2000 Aug; 11(8):985-91. PubMed ID: 11038035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
    ten Bokkel Huinink WW; Prove AM; Piccart M; Steward W; Tursz T; Wanders J; Franklin H; Clavel M; Verweij J; Alakl M
    Ann Oncol; 1994 Jul; 5(6):527-32. PubMed ID: 7918124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
    Catimel G; Verweij J; Mattijssen V; Hanauske A; Piccart M; Wanders J; Franklin H; Le Bail N; Clavel M; Kaye SB
    Ann Oncol; 1994 Jul; 5(6):533-7. PubMed ID: 7918125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
    Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
    J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
    Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
    J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
    Kouroussis C; Androulakis N; Kakolyris S; Souglakos J; Kotsakis T; Mavroudis D; Katsogridakis K; Vardakis N; Hatzidaki D; Samonis G; Vlachonikolis J; Georgoulias V
    J Clin Oncol; 1999 Mar; 17(3):862-9. PubMed ID: 10071277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.